SANTA CRUZ BIOTECHNOLOGY, INC.

MYBPHL (N-16): sc-248025

SANTA CRUZ BIOTECHNOLOGY

The Power to Question

BACKGROUND

MYBPHL (myosin-binding protein H-like) is a 354 amino acid protein that belongs to the MyBP family and immunoglobulin superfamily. MYBPHL contains one fibronectin type-III domain and two Ig-like C2-type (immunoglobulin-like) domains, and is encoded by a gene that maps to human chromosome 1p13.3. Human chromosome 1 spans 260 million base pairs, contains over 3,000 genes and comprises nearly 8% of the human genome. Chromosome 1 houses a large number of disease-associated genes, including those that are involved in familial adenomatous polyposis, Stickler syndrome, Parkinson's disease, Gaucher disease, schizophrenia and Usher syndrome. Aberrations in chromosome 1 are found in a variety of cancers, including head and neck cancer, malignant melanoma and multiple myeloma.

REFERENCES

1. Eudy, J.D., Weston, M.D., Yao, S., Hoover, D.M., Rehm, H.L., Ma-Edmonds, M., Yan, D., Ahmad, I., Cheng, J.J., Ayuso, C., Cremers, C., Davenport, S., Moller, C., Talmadge, C.B., Beisel, K.W., Tamayo, M., Morton, C.C., et al. 1998. Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. Science 280: 1753-1757.
2. Tayebi, N., Callahan, M., Madike, V., Stubblefield, B.K., Orvisky, E., Krasnewich, D., Fillano, J.J. and Sidransky, E. 2001. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. Mol. Genet. Metab. 73: 313-321.
3. Plasilova, M., Russell, A.M., Wanner, A., Wolf, A., Dobbie, Z., Müller, H.J. and Heinimann, K. 2004. Exclusion of an extracolonic disease modifier locus on chromosome 1p33-36 in a large Swiss familial adenomatous polyposis kindred. Eur. J. Hum. Genet. 12: 365-371.
4. Betarbet, R., Anderson, L.R., Gearing, M., Hodges, T.R., Fritz, J.J., Lah, J.J. and Levey, A.I. 2008. Fas-associated factor 1 and Parkinson's disease. Neurobiol. Dis. 31: 309-315.
5. Holliday, E.G., Nyholt, D.R., Tirupati, S., John, S., Ramachandran, P., Ramamurti, M., Ramadoss, A.J., Jeyagurunathan, A., Kottiswaran, S., Smith, H.J., Filippich, C., Nertney, D.A., Nancarrow, D.J., et al. 2009. Strong evidence for a novel schizophrenia risk locus on chromosome 1p31.1 in homogeneous pedigrees from Tamil Nadu, India. Am. J. Psychiatry 166: 206-215.
6. Balcárková, J., Urbánková, H., Scudla, V., Holzerová, M., Bacovský, J., Indrák, K. and Jarosová, M. 2009. Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma. Cancer Genet. Cytogenet. 192: 68-72.
7. Yokoi, T., Koide, R., Matsuoka, K., Nakagawa, A. and Azuma, N. 2009. Analysis of the vitreous membrane in a case of type 1 Stickler syndrome. Graefes Arch. Clin. Exp. Ophthalmol. 247: 715-718.

CHROMOSOMAL LOCATION

Genetic locus: MYBPHL (human) mapping to 1p13.3; Mybphl (mouse) mapping to 3 F3.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

SOURCE

MYBPHL (N-16) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of MYBPHL of human origin.

PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-248025 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

MYBPHL (N-16) is recommended for detection of MYBPHL of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000); non cross-reactive with MYBPH.

MYBPHL (N-16) is also recommended for detection of MYBPHL in additional species, including equine, canine, bovine and porcine.

Suitable for use as control antibody for MYBPHL siRNA (h): sc-78969, MYBPHL siRNA (m): sc-149733, MYBPHL shRNA Plasmid (h): sc-78969-SH, MYBPHL shRNA Plasmid (m): sc-149733-SH, MYBPHL shRNA (h) Lentiviral Particles: sc-78969-V and MYBPHL shRNA (m) Lentiviral Particles: sc-149733-V.

Molecular Weight of MYBPHL: 39 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.